Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina

Am J Cardiol. 1994 Sep 1;74(5):424-9. doi: 10.1016/0002-9149(94)90896-6.

Abstract

Among patients with recent-onset unstable angina and evidence of ischemia or coronary artery disease, the incidence of subsequent cardiovascular events is high. The aim of this study was to investigate, in this high-risk population, whether unstable angina was associated with abnormalities of tissue-type plasminogen activator (t-PA) or plasminogen activator inhibitor (PAI) activities and whether, in a prospective study, any of these parameters would identify patients with an adverse cardiovascular prognosis. A group of 22 high-risk patients with unstable angina (64% event rate at 3 months) was studied prospectively for 12 weeks, and the fibrinolytic parameters measured at presentation were related to subsequent cardiovascular progress. A group of 20 age- and sex-matched healthy subjects acted as control subjects. Patients who had subsequent cardiovascular events (acute myocardial infarction or severe recurrent angina +/- intervention) had significantly elevated PAI activity at presentation compared with both those who remained event-free (p < 0.05) or with control subjects (p < 0.02). In addition, basal activation of fibrinolysis was demonstrated in unstable angina at presentation; this persisted at 9 weeks in patients with a favorable outcome (p < 0.02 vs control subjects), whereas it was no longer evident in those who developed cardiac events. These findings suggest that measurements of t-PA/PAI activity may reflect the underlying pathophysiologic state and relate to subsequent cardiovascular events in unstable angina.

MeSH terms

  • Aged
  • Angina, Unstable / drug therapy
  • Angina, Unstable / physiopathology*
  • Blood Coagulation Factors / drug effects
  • Female
  • Fibrinolysis / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Plasminogen Inactivators / pharmacology*
  • Predictive Value of Tests
  • Prospective Studies
  • Tissue Plasminogen Activator / pharmacology*

Substances

  • Blood Coagulation Factors
  • Plasminogen Inactivators
  • Tissue Plasminogen Activator